We are live on
!
Find out more
JJ
Johnson & Johnson Portfolio holdings
AUM
$799M
Turnover
17.65%
1-Year Est. Return
253.51%
This Fund
S&P 500
This Quarter
Est. Return
-5.59%
1 Year Est. Return
+253.51%
3 Year Est. Return
+280.64%
5 Year Est. Return
+320.83%
10 Year Est. Return
–
AUM
$401M
AUM Growth
-$4.01B
(-91%)
Cap. Flow
-$3.95B
Cap. Flow
% of AUM
-985.8%
Top 10 Holdings %
Top 10 Hldgs %
93.19%
Holding
25
New
3
Increased
–
Reduced
–
Closed
5
Avg Time Held
2
years
Top 10 Avg Time Held
1.3
years
Top 20 Avg Time Held
1.9
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Rapport Therapeutics
RAPP
|
+$57.8M |
| 2 |
Contineum Therapeutics
CTNM
|
+$31.9M |
| 3 |
Rallybio
RLYB
|
+$6.16M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Kenvue
KVUE
|
+$3.91B |
| 2 |
Fusion Pharmaceuticals Inc. Common Shares
FUSN
|
+$78.3M |
| 3 |
Shockwave Medical, Inc. Common Stock
SWAV
|
+$54.3M |
| 4 |
Clearside Biomedical
CLSD
|
+$260K |
| 5 |
TCON
TRACON Pharmaceuticals, Inc. Common Stock
TCON
|
+$36.1K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| 2 | Consumer Staples | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
Protagonist Therapeutics
PTGX
$8.82B
| $84.9M | 21.18% |
2,449,183
| – | – |
2021 Q3
11 quarters
|
|
|
2
Rapport Therapeutics
RAPP
$1.36B
| $58.1M | 14.5% |
+2,498,051
| New | +$57.8M |
2024 Q2
0 quarters
|
|
3
CVRx
CVRX
$35.7M
| $49.2M | 12.28% |
4,103,430
| – | – |
2021 Q3
11 quarters
|
|
4
Legend Biotech
LEGN
$3.7B
| $36.1M | 9% |
814,586
| – | – |
2021 Q3
11 quarters
|
|
|
5
Contineum Therapeutics
CTNM
$306M
| $34.9M | 8.7% |
+1,979,173
| New | +$31.9M |
2024 Q2
0 quarters
|
|
6
Nanobiotix
NBTX
$1.08B
| $28.1M | 7.02% |
5,623,816
| – | – |
2023 Q3
3 quarters
|
|
7
MeiraGTx Holdings
MGTX
$904M
| $28M | 6.98% |
6,641,064
| – | – |
2021 Q3
11 quarters
|
|
8
Procept Biorobotics
PRCT
$1B
| $21.9M | 5.46% |
357,939
| – | – |
2021 Q3
11 quarters
|
|
9
Neumora Therapeutics
NMRA
$66.6M
| $18.2M | 4.54% |
1,849,445
| – | – |
2023 Q3
3 quarters
|
|
10
Xencor
XNCR
$1.74B
| $14.2M | 3.53% |
748,062
| – | – |
2021 Q4
10 quarters
|
|
11
Fate Therapeutics
FATE
$232M
| $11.1M | 2.77% |
3,379,064
| – | – |
2021 Q3
11 quarters
|
|
12
Arrowhead Research
ARWR
$8.25B
| $6.44M | 1.61% |
247,598
| – | – |
2021 Q3
11 quarters
|
|
|
13
Rallybio
RLYB
$89.8M
| $4.87M | 1.22% |
+454,545
| New | +$6.16M |
2024 Q2
0 quarters
|
|
14
Nano X Imaging
NNOX
$40.1M
| $1.17M | 0.29% |
158,852
| – | – |
2021 Q4
10 quarters
|
|
15
Vor Biopharma
VOR
$1.11B
| $1.07M | 0.27% |
53,733
| – | – |
2021 Q3
11 quarters
|
|
16
Aldeyra Therapeutics
ALDX
$47.7M
| $992K | 0.25% |
299,669
| – | – |
2021 Q3
11 quarters
|
|
|
HLSQ
17
Tessera Defense and Homeland Security Inc.
HLSQ
$2.15M
| $646K | 0.16% |
1,012
| – | – |
2021 Q3
11 quarters
|
|
18
Standard BioTools
LAB
$248M
| $552K | 0.14% |
311,967
| – | – |
2024 Q1
1 quarter
|
|
19
Adicet Bio
ACET
$45.8M
| $441K | 0.11% |
22,780
| – | – |
2021 Q3
11 quarters
|
|
20
Senseonics Holdings Inc
SENS
$428M
| $21.8K | 0.01% |
2,731
| – | – |
2021 Q3
11 quarters
|
|
|
21
DELISTED
Clearside Biomedical
CLSD
| – | – |
-11,309
| Closed | -$260K | – |
|
|
22
Kenvue
KVUE
$34.6B
| – | – |
-182,329,550
| Closed | -$3.91B | – |
|
|
TCON
23
DELISTED
TRACON Pharmaceuticals, Inc. Common Stock
TCON
| – | – |
-4,200
| Closed | -$36.1K | – |
|
|
24
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
| – | – |
-3,670,516
| Closed | -$78.3M | – |
|
|
25
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
| – | – |
-166,812
| Closed | -$54.3M | – |
|
Similar funds
SEM
TI
GIM
QCMNJ
LOPW
HW
CCM
LWM
Johnson & Johnson's Q2 2024 Portfolio in Review
As of Q2 2024, Johnson & Johnson held 25 positions worth $401M, down 91% from $4.41B the previous quarter. Its ten largest holdings account for 93% of the portfolio.
Johnson & Johnson withdrew a net $3.95B in Q2 2024, closing 5 positions. Its most notable exit was Kenvue, an estimated $3.91B position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 11% a quarter earlier, followed by Consumer Staples.
Against the trend, Johnson & Johnson opened a new position in Rapport Therapeutics worth $58.1M.
- Johnson & Johnson's largest Q2 2024 buy was Rapport Therapeutics: 2,498,051 shares worth $58.1M.
- Johnson & Johnson fully exited Kenvue in Q2 2024, selling an estimated $3.91B.
- Johnson & Johnson's ten largest holdings make up 93% of its $401M portfolio in Q2 2024.
- Johnson & Johnson opened 3 new positions and closed 5 in Q2 2024.
- Johnson & Johnson's portfolio value fell 91% quarter-over-quarter to $401M.
Based on Johnson & Johnson's 13F filing for Q2 2024, filed 9 Aug 2024.